STAT+: A standing ovation for RevMed, and caution for Akeso
Adam Feuerstein, Matthew Herper, Katherine MacPhail, Angus Chen·
·1 min read
·
0 reactions
·
0 comments
·
21 views
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Original article
STAT · Adam Feuerstein, Matthew Herper, Katherine MacPhail, Angus Chen
Anonymous · no account needed
Discussion
0 commentsMore from STAT
Opinion: How the Amish think about vaccines, health care costs, and much more
STAT·12
Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
STAT·12
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
STAT·15
STAT+: Up and down the ladder: The latest comings and goings
STAT·12
STAT+: Will Makary’s FDA voucher program survive?
STAT·15
STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher program
STAT·24